Bicara Therapeutics (BCAX) Invested Capital (2023 - 2026)

Bicara Therapeutics (BCAX) has 4 years of Invested Capital data on file, last reported at $514.0 million in Q1 2026.

• For the quarter ending Q1 2026, Invested Capital rose 11.98% year-over-year to $514.0 million; the trailing twelve-month figure through Mar 2026 stood at $514.0 million (up 11.98% YoY), and the FY2025 full-year result was $401.5 million, down 18.38% from the prior year.
• Invested Capital for Q1 2026 stood at $514.0 million, up from $401.5 million in the prior quarter.
• Across five years, Invested Capital topped out at $514.0 million in Q1 2026 and bottomed at -$174.8 million in Q2 2024.
• The 4-year median for Invested Capital is $402.8 million (2025), against an average of $235.7 million.
• The widest annual swing landed in 2024, when Invested Capital soared 471.64%; it then fell 20.95% in 2025.
• A 4-year view of Invested Capital shows it stood at -$148.8 million in 2023, then soared by 430.63% to $491.9 million in 2024, then fell by 18.38% to $401.5 million in 2025, then gained by 28.02% to $514.0 million in 2026.
• The last three Invested Capital figures came in at $514.0 million (Q1 2026), $401.5 million (Q4 2025), and $402.8 million (Q3 2025), per Business Quant data.

Peer Comparison